Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Biomateiral Co's revenue for the
three
months ended in Jun. 2026 was NT$36.9 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$182.3 Mil.
Taiwan Biomateiral Co's Revenue per Share for the
three
months ended in Jun. 2026 was NT$0.88.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$4.33.
Warning Sign:
Taiwan Biomateiral Co Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Taiwan Biomateiral Co was 13.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 18.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 42.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 65.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Taiwan Biomateiral Co's highest 3-Year average Revenue per Share Growth Rate was 240.50% per year. The lowest was -21.00% per year. And the median was 65.15% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Taiwan Biomateiral Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Biomateiral Co Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Biomateiral Co's Revenue distribution charts can be found below:
* The bar in red indicates where Taiwan Biomateiral Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$182.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Biomateiral Co (ROCO:6649) has a Revenue of NT$182.3 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Taiwan Biomateiral Co and its competitors.
Is Taiwan Biomateiral Co's Revenue too high?
Taiwan Biomateiral Co's current Revenue is NT$182.3 Mil. Overall, Taiwan Biomateiral Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Biomateiral Co's Revenue compare to ABT and SYK?
Taiwan Biomateiral Co's Revenue of NT$182.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Taiwan Biomateiral Co and its competitors. Taiwan Biomateiral Co's current Revenue is NT$182.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Biomateiral Co stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Biomateiral Co (ROCO:6649) is currently considered Possible Value Trap. The stock's GF Value™ is NT$58.51, compared to a current price of NT$35.40 — trading 39.5% below its estimated fair value. The current Revenue is NT$182.3 Mil. Taiwan Biomateiral Co's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Taiwan Biomateiral Co (ROCO:6649), the current Revenue is NT$182.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Biomateiral Co (ROCO:6649) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Biomateiral Co stock appears to be undervalued.
The current stock price of NT$35.40 is trading 39.5% below its estimated GF Value™ of NT$58.51.
GuruFocus considers Taiwan Biomateiral Co to be Possible Value Trap.
Key valuation signals for ROCO:6649:
Revenue: NT$182.3 Mil
GF Value™: NT$58.51 vs. price of NT$35.40 (39.5% below fair value)
No single metric tells the full story. See the ROCO:6649 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Biomateiral Co Ltd is an applied technology Research and Development Institute in Taiwan. It is engaged in the research and development and sales of implantable medical devices. The company's products include Foamagen, stroke interventional treatment devices.
80GF Score
Get the complete analysis for ROCO:6649
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6649 has been successfully added to your 
